Work

The pyruvate kinase activator etavopivat (FT-4202) limits pulmonary and systemic sequelae of sepsis in a mouse LPS model

Year: 2026

Type: article

Abstract: Etavopivat (FT-4202), a RBC-selective pyruvate kinase activator (PKRA), limited weight loss, inflammatory cytokines, neutrophil gelatinase-associated lipocalin (NGAL) elevation, and neutrophilia in a mouse sepsis model. We show for the first time that a PKRA promotes ATP export from mouse RBCs, and this could contribute to the benefits of this RBC-directed therapeutic.

Source: American Journal of Physiology-Lung Cellular and Molecular Physiology

DOI: 10.1152/ajplung.00389.2025